Article

Retina center teams up with high school student

Fort Myers, FL-Last year Sabrina Prabakaran, a high school student at Canterbury School, met with the Retina Health Center team to discuss a research project to investigate further the value of bevacizumab (Avastin) in the treatment of wet age-related macular degeneration (AMD). The drug is currently approved for the treatment of colon cancer. The research project is now complete, and the findings show that nearly half of patients with AMD and taking bevacizumab showed improvement in vision.

Fort Myers, FL-Last year Sabrina Prabakaran, a high school student at Canterbury School, met with the Retina Health Center team to discuss a research project to investigate further the value of bevacizumab (Avastin) in the treatment of wet age-related macular degeneration (AMD). The drug is currently approved for the treatment of colon cancer. The research project is now complete, and the findings show that nearly half of patients with AMD and taking bevacizumab showed improvement in vision.

"Longer follow-up will be needed to determine if these results will stay consistent long term, but for now we are very excited about the preliminary findings," said Alexander Eaton, MD, FACS, director, Macular Degeneration Research Center, Retina Health Center. "Avastin has restored vision and in some cases, given people their vision back."

This isn't the first time that Prabakaran has studied medicine. Last fall, as a ninth grader, she was a finalist in the Discovery Channel Young Scientist Challenge with "Effect of cardiac rehabilitation on patients with coronary artery disease: post-exercise response of blood pressure and heart rate."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
© 2025 MJH Life Sciences

All rights reserved.